Innospera Pharma Welcomes New CEO François Ravenelle
Innospera Pharma Inc., a biotechnology company that develops treatments for inflammatory and metabolic diseases, has announced the appointment of François Ravenelle, PhD, as its new President and Chief Executive Officer, effective immediately.
Dr. Ravenelle brings over 20 years of experience in the biotech field, having most recently served as the President and CEO of Inversago Pharma. There, he played a key role in raising over $100 million and led the company to a significant acquisition by Novo Nordisk valued at nearly $1 billion.
"I’m excited to be joining Innospera at such an important time," said Dr. Ravenelle. He highlighted the company’s lead product, which shows promise in treating chronic conditions like idiopathic pulmonary fibrosis. "We have solid preclinical data, and I believe Innospera is poised to make a real difference in addressing inflammatory diseases," he added.
Pierre Laurin, Executive Chairman of the Board and founder, praised Ravenelle’s appointment, noting it comes just after a successful seed financing round. "His leadership and vision will be crucial as we move towards clinical development," Laurin stated. He acknowledged the support from investors like Investissement Québec, Seido Capital, and Anges Québec, emphasizing Innospera’s potential within America’s vibrant life science community.
This transition marks a new chapter for Innospera as it aims to advance its innovative approaches to treating diseases that currently have limited options.
